S-1: Modular Medical Seeks $12M Amidst Going Concern Doubts

Modular Medical, a pre-revenue medical device company, is conducting a best-efforts offering of up to $12 million in common stock and warrants to fund operations and commercialize its Pivot insulin pump, despite significant operating losses and going concern uncertainty.

Summary

• Modular Medical, Inc. (MODD) is a pre-revenue medical device company focused on developing innovative insulin pumps, specifically its next-generation Pivot patch pump.
• The company is undertaking a best-efforts public offering to raise up to $12,000,000 through the sale of common stock and accompanying common warrants, or pre-funded warrants and common warrants.
• The assumed combined public offering price for each share of common stock and one common warrant is $0.5091, based on the Nasdaq closing price on February 19, 2026.
• Net proceeds from the offering are estimated to be approximately $10.9 million if the maximum amount is sold, which will be used for general corporate purposes, including repayment of a $350,000 promissory note to the CEO, funding operations through FDA approval of the Pivot product, initial commercialization, R&D, and manufacturing.
• The company reported a cash and cash equivalents balance of $2.9 million and an accumulated deficit of $106.6 million as of December 31, 2025.
• Net losses were approximately $21.9 million for the nine months ended December 31, 2025, and $18.8 million for the year ended March 31, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for at least one year from the financial statement issuance date.
• The company received FDA clearance for its initial MODD1 pump in September 2024 but intends to commercialize its next-generation Pivot product, for which a 510(k) premarket notification was submitted on November 13, 2025, with FDA clearance expected by March 31, 2026, or shortly thereafter.
• Modular Medical is currently non-compliant with Nasdaq's minimum $1 bid price rule and has received an extension until June 29, 2026, to regain compliance, with shareholders authorizing a reverse stock split if necessary.
• The company's authorized common stock was increased from 100,000,000 to 250,000,000 shares on January 23, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the explicit 'going concern' warning, substantial accumulated deficit, ongoing significant operating losses, and the immediate need for additional capital. The Nasdaq delisting threat further compounds the financial instability, overshadowing product development progress.

Positives

• Received FDA clearance for the initial MODD1 pump in September 2024.
• Submitted 510(k) premarket notification for the next-generation Pivot product, with FDA clearance expected by March 31, 2026, or shortly thereafter.
• Engaged Phillips Medisize, a large tier-one medical device manufacturer, as a manufacturing partner for the Pivot product, aiming for rapid scaling and lower costs.
• Holds 6 U.S. patents and 4 foreign patents related to its proprietary fluid movement technology and insulin delivery methodology, with additional applications pending.

Negatives

• The company is pre-revenue and has a history of significant operating losses, including $21.9 million for the nine months ended December 31, 2025, and $18.8 million for the year ended March 31, 2025.
• An accumulated deficit of approximately $106.6 million as of December 31, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• Current cash and cash equivalents of $2.9 million are not believed to be sufficient to fund operations for the next 30 days, necessitating additional capital raises.
• The company is non-compliant with Nasdaq's minimum $1 bid price requirement and faces potential delisting if compliance is not regained by June 29, 2026.
• The offering is on a 'reasonable best efforts' basis with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital to meet its objectives.
• Purchasers in this offering will experience immediate and substantial dilution in the net tangible book value of their investment, estimated at $0.34 per share.

Risks

• The company might not be able to continue as a going concern due to expected operating losses and cash burn.
• Substantial additional funding is required to complete product development and operations, which may not be available or could substantially dilute existing stockholders.
• A limited operating history and historical financial information make it difficult to evaluate performance and future success.
• Future cash requirements may differ significantly from current estimates, potentially leading to delays or curtailment of product development.
• A substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price.
• There is no public market for the warrants being offered, limiting their liquidity and making them speculative in nature.
• The company may not be able to utilize a significant portion of its net operating losses and tax credits due to ownership changes.
• Technological breakthroughs in diabetes monitoring, treatment, or prevention could render insulin pump products obsolete.
• Failure to attract and retain skilled directors, executives, employees, and consultants could impair product development and commercialization.
• Reliance on third parties for development, manufacturing, sales, marketing, and regulatory submissions poses risks if these parties fail to perform.
• Inability to identify, negotiate, and maintain strategic alliances could hinder product development and commercialization.
• Failure to receive necessary regulatory clearance or approvals for insulin pump products, particularly the Pivot, could harm operations.
• Obtaining marketing authorization in the U.S. does not guarantee approval in foreign jurisdictions, incurring additional costs and potential delays.
• Competitors may develop more effective, safer, or less expensive products, impacting market acceptance.
• Inability to successfully scale-up manufacturing in sufficient quality and quantity could delay commercialization.
• Dependence on third-party suppliers makes the company vulnerable to supply shortages and price increases.
• Potential product liability and other claims could materially impact the business and financial condition.
• Legislative, regulatory, or medical cost reimbursement changes may adversely impact the business.
• Extensive FDA regulation could restrict sales and marketing and incur significant costs.
• Clinical testing results may not demonstrate sufficient safety and efficacy for product approval.
• Inability to obtain and maintain intellectual property protection could adversely affect competitive advantage.
• Infringement lawsuits from third parties would be costly and time-consuming.
• Failure to protect the confidentiality of proprietary information could adversely affect technology and product value.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Healthcare reform and drug-pricing reform laws could adversely affect products and financial condition.
• Failure to comply with FDA's quality system regulations could interrupt manufacturing and distribution.
• Disputes with contract partners over intellectual property or other matters could significantly affect the business.
• Insulin pump products may be subject to recalls, harming reputation and financial results.
• Lack of reimbursement and insurance coverage for the Pivot product could prevent significant revenue generation.
• Oversight by the SEC and other regulatory agencies, including investigations, could divert management's focus and harm reputation.
• As a smaller reporting company, reduced disclosure requirements may make common stock less attractive to investors.
• Potential volatility of the common stock price could negatively affect investment.
• Provisions in the articles of incorporation and bylaws might delay or prevent a change-of-control transaction.
• Inability to establish and maintain an effective system of internal controls could lead to inaccurate financial reporting or fraud.
• Sustained inflation could have a material adverse effect on business, financial condition, results of operations, and liquidity.
• The board of directors can adopt recapitalizations (forward or reverse splits) without stockholder approval.

Future Outlook

The company intends to use the net proceeds from this offering to fund operations through the expected FDA approval of its Pivot product, commence initial commercialization of Pivot, fund additional research and development activities, further develop manufacturing and production capabilities, and make related capital expenditures. The company expects to incur losses for the foreseeable future as it continues development and seeks regulatory clearances. Its ability to continue as a going concern depends on raising additional capital.

Industry Context

StockSavvy.ai notes that Modular Medical operates in the intensely competitive diabetes treatment sector, which is characterized by rapid technological change and product innovation. The company aims to disrupt the market by offering a novel two-part patch pump, Pivot, designed to be simpler and more cost-effective than existing insulin pumps, thereby expanding the market beyond 'super users' to a mass market, including Type 1 and Type 2 diabetes patients. This strategy directly addresses the high cost and complexity barriers that currently limit pump adoption, which is a significant industry trend. However, the market includes large, established medical device companies with substantially greater financial resources and experience in development, regulatory approvals, manufacturing, and commercialization.

Comparison to Industry Standards

• Modular Medical's Pivot pump aims to break the 'cost vs. functionality curve' prevalent in the insulin pump space, suggesting a differentiation strategy against established players.
• Existing competitors like Medtronic, Inc., Tandem Diabetes Care, Inc., and Insulet Corporation offer products that are often expensive, with popular models exceeding $4,000 in reimbursement and requiring significant patient co-pays, which Modular Medical seeks to undercut.
• The company's use of 'parts from high volume consumer electronics manufacturing lines' for its pump products is a distinct approach compared to traditional medical device manufacturing, potentially enabling lower costs and faster scaling, a key competitive advantage if successful.
• The Pivot product's design, emphasizing simplicity in bolus delivery and a removable patch form factor, targets the 'Almost Pumpers' market, a segment potentially underserved by the more complex offerings of current market leaders.

Corporate Governance

Related Party Transactions

• On February 23, 2026, the company issued a secured promissory note to James E. Besser, its chief executive officer, providing a $350,000 revolving credit facility at 12% interest, due March 25, 2026. As of the filing date, $200,000 had been borrowed under this note.

Stakeholder Impact

• Shareholders: Face significant dilution from the current offering and potential future capital raises, risk of substantial loss of investment due to going concern doubts, and potential delisting from Nasdaq. Existing beneficial ownership is concentrated, limiting influence for other shareholders.
• Employees: Job security is tied to the company's ability to raise additional capital and achieve profitability, given the 'going concern' warning.
• Customers: Potential for new, simpler insulin pump products (Pivot) if commercialization is successful, but product availability and long-term support depend on the company's financial viability.
• Creditors: The company's ability to repay debts, including the promissory note to the CEO, is uncertain given its financial condition and reliance on future capital raises.

Next Steps

• Obtain required regulatory approval from the FDA for the Pivot product, expected by March 31, 2026, or shortly thereafter.
• Initiate commercial launch of the Pivot product after receiving FDA approval.
• Obtain regulatory clearance to market and sell the Pivot product in foreign jurisdictions.
• Improve the manufacturability and usability of the Pivot product.
• Develop new pump products.
• Regain compliance with Nasdaq's minimum bid price requirement by June 29, 2026, potentially by effecting a reverse stock split.
• Raise additional capital through debt or equity arrangements to support future operations and address going concern issues.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about our ability to continue as a going concern,' has significant accumulated losses, and insufficient cash to fund operations for the next 30 days. The ongoing Nasdaq minimum bid price non-compliance and the need for continuous dilutive capital raises indicate severe financial distress and high operational risk. While product development is ongoing, the fundamental financial instability makes this a highly speculative and risky investment, warranting a strong sell recommendation for seasoned investors.

Keywords

Insulin pump, Diabetes treatment, Medical device, S-1 Registration, Modular Medical, MODD, Pivot pump, FDA clearance, Capital raise, Warrants, Nasdaq delisting, Going concern, Biotechnology, Healthcare technology